LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have received an average recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $94.63.

Several research analysts have weighed in on the stock. Wells Fargo & Company assumed coverage on shares of LeMaitre Vascular in a research note on Thursday. They set an “equal weight” rating and a $95.00 target price for the company. StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Barrington Research lifted their target price on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a report on Friday, November 1st. Finally, Oppenheimer restated an “outperform” rating and set a $93.00 price target (up from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of LMAT. Conestoga Capital Advisors LLC raised its position in LeMaitre Vascular by 1.9% in the 3rd quarter. Conestoga Capital Advisors LLC now owns 1,978,351 shares of the medical instruments supplier’s stock valued at $183,769,000 after purchasing an additional 36,850 shares in the last quarter. Copeland Capital Management LLC raised its holdings in LeMaitre Vascular by 0.7% in the fourth quarter. Copeland Capital Management LLC now owns 1,172,015 shares of the medical instruments supplier’s stock valued at $107,990,000 after acquiring an additional 8,623 shares in the last quarter. State Street Corp raised its holdings in LeMaitre Vascular by 3.6% in the third quarter. State Street Corp now owns 822,085 shares of the medical instruments supplier’s stock valued at $76,363,000 after acquiring an additional 28,525 shares in the last quarter. Congress Asset Management Co. lifted its stake in LeMaitre Vascular by 1.8% in the fourth quarter. Congress Asset Management Co. now owns 722,325 shares of the medical instruments supplier’s stock worth $66,555,000 after acquiring an additional 13,009 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in LeMaitre Vascular by 1.4% during the 4th quarter. Geode Capital Management LLC now owns 550,260 shares of the medical instruments supplier’s stock worth $50,711,000 after acquiring an additional 7,737 shares in the last quarter. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

LeMaitre Vascular Stock Up 1.7 %

Shares of LeMaitre Vascular stock opened at $98.65 on Tuesday. The business’s fifty day simple moving average is $95.94 and its 200-day simple moving average is $93.61. The firm has a market cap of $2.22 billion, a PE ratio of 53.91, a price-to-earnings-growth ratio of 2.19 and a beta of 0.96. LeMaitre Vascular has a 52 week low of $59.87 and a 52 week high of $109.58.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.